Johns Hopkins Hospital

Running trials

• Recruiting

  DK222 Study at Hopkins

  NCT07140315· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Not yet recruiting

  Peer-led, Mobile App Supported Linkage to Opioid Use Disorder Treatment

  NCT07900828· Johns Hopkins University· Source

• Not yet recruiting

  Deep Brain Stimulation for Treatment-Resistant Schizophrenia

  NCT07592611· Johns Hopkins University· Source

• Not yet recruiting

  A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

  NCT07789015· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Guanfacine and Cromolyn Sodium for POTS: The DBPOTS Trial

  NCT07757555· Early phase 1· Johns Hopkins University· Source

• Not yet recruiting

  Cerebellar Brain Stimulation Plus Language Therapy for People at Risk of Poor Aphasia Recovery After Stroke

  NCT07912242· Johns Hopkins University· Source

• Not yet recruiting

  Personalized Closed-Loop Brain Stimulation for Patients With Primary Progressive Aphasia

  NCT07511179· Johns Hopkins University· Source

• Not yet recruiting

  Personalized Closed-Loop Brain Stimulation for Patients With Mild Cognitive Impairment

  NCT07512193· Johns Hopkins University· Source

• Recruiting

  Imaging Assessment of Swallowing and Speech Muscles in Inclusion Body Myositis

  NCT07823101· Johns Hopkins University· Source

• Enrolling by invitation

  Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome

  NCT07768267· Phase 2· Johns Hopkins University· Source

• Recruiting

  Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors

  NCT07360119· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  Optic Nerve Head Strain in Non-glaucoma Subjects

  NCT07425535· Early phase 1· Johns Hopkins University· Source

• Enrolling by invitation

  Blood-Brain Barrier Integrity and Immune Dynamics in Neuropsychiatric Sequelae of Post-SARS-CoV-2 Onset ME/CFS Versus Pre-Pandemic ME/CFS Patients

  NCT07256795· Johns Hopkins University· Source

• Recruiting

  A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07518186· Phase 3· Janssen Research & Development, LLC· Source

• Enrolling by invitation

  Shortwave Infrared Surgical Imaging Device Study

  NCT07744425· Cision Vision, Inc.· Source

• Recruiting

  WIREDUP: Wearable Insoles for Recurrent Diabetic Ulcer Prevention

  NCT05950659· Johns Hopkins University· Source

• Recruiting

  Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

  NCT07103746· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  PS-002 for the Treatment of IgA Nephropathy in Adults

  NCT07182227· Phase 1/2· Purespring Therapeutics Limited· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  NCT07421700· Phase 1/2· Pfizer· Source

• Recruiting

  A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

  NCT07325526· Phase 2· Boehringer Ingelheim· Source

• Recruiting

  Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

  NCT07108387· Phase 2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Evaluate the Safety and Effectiveness of the Rapidlink Device When Used in Patients Undergoing an Open Surgical Procedure to Repair the Aorta

  NCT07078383· Vascutek Ltd.· Source

• Recruiting

  A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy

  NCT07287982· Phase 2· argenx· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Eli Lilly and Company· Source

• Active, not recruiting

  A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)

  NCT07107945· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

  NCT07223047· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

  NCT07085104· Phase 1· Allogene Therapeutics· Source

• Recruiting

  Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

  NCT07225205· Johns Hopkins University· Source

• Recruiting

  Pediatric Radiation Therapy Registry

  NCT07129317· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service Implementation

  NCT06103370· Johns Hopkins University· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Pfizer· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

  NCT07271017· Phase 1· Johns Hopkins University· Source

• Recruiting

  Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  NCT07101094· Bristol-Myers Squibb· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

  NCT07023289· Phase 2· AbbVie· Source

• Recruiting

  OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

  NCT07136012· Phase 3· Amgen· Source

• Not yet recruiting

  A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis

  NCT06989567· Phase 3· Asklepion Pharmaceuticals, LLC· Source

• Active, not recruiting

  Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP)

  NCT07047716· Phase 3· Gilead Sciences· Source

• Recruiting

  Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  NCT06855277· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension

  NCT06992440· Phase 2· Gustavo A Heresi, MD, MS· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Recruiting

  Safety of HRX215 in Patients After Minor and Major Liver Resection

  NCT06638502· Phase 1/2· HepaRegeniX GmbH· Source

• Recruiting

  External Post-Operative Skull Prosthesis to Prevent Sunken Flap Syndrome in Craniectomy Patients

  NCT06899711· Johns Hopkins University· Source

• Recruiting

  320-detector Computed Tomography to Assess Myocardial Extracellular Volume Fraction in Patients With Atrial Fibrillation Before AF Ablation.

  NCT06308094· Johns Hopkins University· Source

Showing 50 of 158.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Pancreatic cancer9 recruiting
• Bladder cancer7 recruiting
• Childhood cancers6 recruiting
• Lung cancer6 recruiting
• Prostate cancer6 recruiting
• Barrett's oesophagus4 recruiting
• Colorectal cancer4 recruiting
• Dermatomyositis and polymyositis (myositis)4 recruiting
• Frontotemporal dementia4 recruiting
• Sarcoma4 recruiting
• Stroke4 recruiting
• Epilepsy3 recruiting
• Kidney cancer3 recruiting
• Liver and biliary tract cancer3 recruiting
• Alzheimer disease2 recruiting
• Coronary artery disease2 recruiting
• Cystic fibrosis2 recruiting
• Diabetic foot ulcer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Head and neck cancer2 recruiting
• Heart failure2 recruiting
• High blood pressure2 recruiting
• HIV2 recruiting
• Melanoma2 recruiting
• Mild cognitive impairment2 recruiting
• Multiple myeloma2 recruiting
• Neurofibromatosis type 12 recruiting
• Pulmonary arterial hypertension2 recruiting
• Schizophrenia2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Uterine fibroids2 recruiting
• ALS (motor neurone disease)1 recruiting
• Aortic aneurysm1 recruiting
• Aortic stenosis1 recruiting
• Atrial fibrillation1 recruiting
• Cerebral palsy1 recruiting
• Chronic kidney disease1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Endometriosis1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Giant cell arteritis1 recruiting
• Glaucoma1 recruiting
• Glioblastoma1 recruiting
• Hearing loss1 recruiting
• Hyperparathyroidism1 recruiting
• IgA nephropathy1 recruiting
• Irritable bowel syndrome1 recruiting
• Liver cirrhosis1 recruiting
• Long COVID and ME/CFS1 recruiting
• Lupus (SLE)1 recruiting
• Meningioma1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Parkinson disease1 recruiting
• Postural tachycardia syndrome (POTS)1 recruiting
• Sarcoidosis1 recruiting
• Sickle cell disease1 recruiting
• Spinal muscular atrophy1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Recruiting

  The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

  NCT06872892· Phase 3· Boehringer Ingelheim· Source

• Completed

  Mobile Application for Patient Engagement and Physician-Directed Remote Management of Heart Failure

  NCT06750549· University of Michigan· Source

• Withdrawn

  Closed Loop Spinal Cord Stimulation for Neuromodulation of Upper Motor Neuron Lesion Spasticity

  NCT06384170· Johns Hopkins University· Source

• Completed

  Brain Volume and Cardiac Function in Heart Failure

  NCT06623344· Johns Hopkins University· Source

• Completed

  ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

  NCT06526546· Boston Scientific Corporation· Source

• Completed

  A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus

  NCT06362265· Phase 1· Eli Lilly and Company· Source

• Completed

  Artificial Intelligence-based Video Analysis to Detect Infantile Spasms

  NCT06315829· Johns Hopkins University· Source

• Completed

  RECOVER-AUTONOMIC Platform Protocol

  NCT06305780· Phase 2· Kanecia Obie Zimmerman· Source

• Terminated

  Surveillance of Regional Nodal Basins in Patients With Primary High Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

  NCT05956795· Johns Hopkins University· Source

• Completed

  Enhanced Recovery After Surgery (ERAS) for Ambulatory TURBT

  NCT05905276· Johns Hopkins University· Source

• Terminated

  ADSTILADRIN Early Utilization and Outcomes in the Real World Setting

  NCT06026332· Ferring Pharmaceuticals· Source

• Completed

  The Role of IL5 in Epithelial Cell Integrity

  NCT05895929· Early phase 1· Johns Hopkins University· Source

• Completed

  RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

  NCT05595369· Phase 2· Kanecia Obie Zimmerman· Source

• Completed

  Feasibility of a Digital Goals-of-Care Decision Aid for Clinicians and Families of Patients With SABI

  NCT05671874· University of Massachusetts, Worcester· Source

• Terminated

  Deep Brain Stimulation in Treatment Resistant Schizophrenia

  NCT02361554· Johns Hopkins University· Source

• Completed

  A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation

  NCT05443594· Boston Scientific Corporation· Source

• Completed

  A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

  NCT05668741· Phase 1/2· Vertex Pharmaceuticals Incorporated· Source

• Completed

  PRotein Optimization With eXercise to Improve MUscle Mass and Functional outcomeS

  NCT05296096· Boston Children's Hospital· Source

• Completed

  Conditioned Open-label Placebo (COLP) for Peri-operative Pain Management in Patients With Head and Neck Cancer

  NCT04973748· Johns Hopkins University· Source

• Withdrawn

  Neoadjuvant Short-course Hypofractionated PBT for Non-metastatic RPS

  NCT05302570· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  NCT05327114· Phase 2/3· Janssen Research & Development, LLC· Source

• Completed

  Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children

  NCT04989790· Johns Hopkins University· Source

• Completed

  An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

  NCT05477524· Phase 3· Pfizer· Source

• Completed

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema

  NCT06850922· Phase 1/2· Genentech, Inc.· Source

• Completed

  A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

  NCT05232825· Phase 3· Hoffmann-La Roche· Source

• Terminated

  Patient-Reported Erectile Recovery and Quality of Life Outcomes With Lyopreserved Placental Tissue Applied Directly Over Neurovascular Bundle During Nerve Sparing Radical Prostatectomy Versus Standard of Care

  NCT05366842· Phase 2· Johns Hopkins University· Source

• Completed

  A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

  NCT04773782· Phase 1/2· Blueprint Medicines Corporation· Source

• Terminated

  A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT05169684· Phase 2· Bristol-Myers Squibb· Source

• Completed

  Radiofrequency Ablation of Papillary Thyroid Microcarcinoma

  NCT05132205· Johns Hopkins University· Source

• Terminated

  Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer

  NCT04982224· Phase 1· Regeneron Pharmaceuticals· Source

• Completed

  A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  NCT05096221· Phase 3· Sarepta Therapeutics, Inc.· Source

• Completed

  Effectiveness and Cost-Effectiveness of Fully-Automated Digital vs. Human Coach-Based Diabetes Prevention Programs

  NCT05056376· Johns Hopkins University· Source

• Completed

  A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

  NCT05047263· Phase 3· Bayer· Source

• Completed

  A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies

  NCT05039177· Phase 1/2· Erasca, Inc.· Source

• Completed

  Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

  NCT04903626· Phase 3· AbbVie· Source

• Terminated

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

  NCT04807972· Phase 1· AbbVie· Source

• Recruiting

  A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

  NCT04775485· Phase 2· Day One Biopharmaceuticals, Inc.· Source

• Completed

  A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

  NCT04729907· Phase 3· Biogen· Source

• Completed

  A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

  NCT04665843· Phase 2· Hoffmann-La Roche· Source

• Terminated

  Peri-Atrial Inflammatory Fat and Atrial Fibrillation

  NCT04186169· Johns Hopkins University· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source

• Terminated

  A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement

  NCT04543188· Phase 1· Pfizer· Source

• Completed

  Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest

  NCT04170062· Johns Hopkins University· Source

• Completed

  Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

  NCT04583501· Early phase 1· Johns Hopkins University· Source

• Completed

  Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

  NCT04575896· Phase 4· Johns Hopkins University· Source

• Completed

  Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

  NCT04435626· Phase 3· Bayer· Source

• Completed

  A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm

  NCT04503551· Phase 3· Hoffmann-La Roche· Source

• Completed

  An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

  NCT04353492· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Emergency Department-Initiated Buprenorphine Validation Network Trial

  NCT04225598· Phase 2· Yale University· Source

• Completed

  Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

  NCT04089566· Phase 3· Biogen· Source

Showing 50 of 74.

Conditions

Diseases this institution publishes on or runs trials for.

• Bladder cancer42 works · 11 trials
• Deep vein thrombosis and pulmonary embolism26 works · 0 trials
• Congenital heart disease16 works · 0 trials
• Neuroendocrine tumours13 works · 0 trials
• Ventricular tachycardia8 works · 0 trials
• Neurofibromatosis type 15 works · 3 trials
• Retinitis pigmentosa4 works · 1 trial